Science & Enterprise subscription

Follow us on Twitter

  • This is nuts. Manufacturing, distribution, and public health infrastructure here are more important than who made t… https://t.co/AOHVdFBlrX
    about 10 hours ago
  • Don't let the perfect be the enemy of the good ... https://t.co/nHtOdudliO
    about 1 day ago
  • Among the tech giants, Apple is the most aggressive in acquiring start-ups developing A.I. applications over the pa… https://t.co/RjpknHBKAR
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Apple Leads in A.I. Acquistions https://t.co/WTof485yka #Science #Business
    about 2 days ago
  • HBCUs still hand out more bachelor's degrees in STEM fields to Blacks than traditionally white institutions, but no… https://t.co/xW2ICnR09b
    about 2 days ago

Please share Science & Enterprise

Mayo Clinic Offering Gene Test to Target Chemotherapy

Chemotherapy (National Institutes of Health)

(National Institutes of Health)

29 April 2014. Mayo Clinic in Rochester, Minnesota now offers cancer patients with solid tumors a test that enables physicians to tailor chemotherapy drugs to the patient’s specific genetic background. The test known as Solid Tumor Targeted Cancer Panel or CANCP is available to patients at the Mayo Clinic and its affiliates worldwide, through the clinic’s medical labs in Rochester.

The test scans specific regions in 50 genes most associated with tumor growth and the body’s response to chemotherapy. This method, called a hotspot panel, focuses only on the areas of the genes known to produce mutations that influence the action of chemotherapy drugs. Thus, physicians can more precisely prescribe chemotherapy drugs that better fit the patient’s genomic profile.

The test is designed to recommend the optimum chemotherapy for solid tumor cancer patients. Solid tumor cancers are those that form abnormal masses and originate in soft tissue or organs, such as lung, skin, prostate, and breast cancer. Benjamin Kipp, the test’s lead designer, says in a clinic statement that the panel aims to provide the physicians with actionable data, “results that oncologists can use to help find the right drug the first time.”

The test requires specimens sent to the Mayo Clinic Medical Laboratories, which are analyzed with next-generation genomic sequencing. Next generation sequencing uses high-throughput computing power to determine the precise order of molecules in an individual’s DNA, and in this case identify variations and mutations in that sequence associated with cancer.

CANCP is the second genetic-based cancer screening test offered by Mayo Clinic. The first test is a 17-gene panel to identify hereditary colon cancer syndrome.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.